
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is well-positioned for growth driven by increasing diagnoses of sleep apnea, an aging population, and rising obesity rates, leading to a structurally expanding market. The company's strategic focus on digital health and investment in clinical data provision enhances its competitive differentiation while allowing for a robust return to shareholders through increased dividends and an aggressive share repurchase strategy. In the latest financial performance, U.S., Canada, and LATAM revenue from masks and other products rose by 12% year-over-year, indicating strong demand and solid revenue growth prospects despite rising operating expenses.
Bears say
ResMed is currently facing a challenging outlook due to the potential market disruption caused by the uptake of GLP-1 drugs, which may negatively impact future sales of its masks and devices used for sleep apnea treatment. Although the company is outpacing market growth, concerns persist regarding its ability to sustain revenue levels in the face of these competing therapies. Moreover, the continued reliance on a significant portion of revenue from the Americas raises risks related to regional market fluctuations and competitive pressures.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares